ChemoMetec A/S afholder telefonkonference den 11. september 2026 kl. 15.00 til præsentation af den kommende årsrapport for 2025/26

ChemoMetec A/S annoncerer udgivelse af årsrapporten for regnskabsåret 2025/26 den 10. september 2026 og afholder efterfølgende telefonkonference den 11. september 2026 kl. 15.00 (engelsk) med CEO Martin Helbo Behrens og CFO Phillip Massie Price. Nyheden indeholder ingen konkrete finansielle resultater eller guidanceændringer, så forventet markedsbevægelse er begrænset.

Analysis

This is more of a sentiment check than a standalone fundamental catalyst. In a niche life-science tools name, the market will care less about the reported year itself and more about whether recurring consumables, installed-base utilization, and pricing power are still offsetting softer biotech capex. If management sounds confident on conversion of instrument placements into follow-on revenue, that supports premium multiples across the small-cap tools cohort; if not, the first-order selloff can spill into peers with similar gross-margin profiles but weaker balance sheets.

The near-term move is likely to be driven by guidance tone, but the more important 1-3 month path is revision risk around backlog and customer spending cadence. A miss here would not just hit EPS; it would signal that analytical instrument demand is normalizing earlier than expected, which typically compresses multiples before it changes absolute earnings. Conversely, any evidence that pharma QC/production demand is more stable than venture-biotech demand would argue this franchise is less cyclical than the market assumes.

Contrarian view: consensus may be over-indexed on broad biotech weakness and underweight the defensiveness of routine testing workflows. That means the stock may not deserve to trade with XBI-type beta if consumables attach rate is intact. The main falsifiers are simple: guide-downs, margin compression, or commentary implying customer destocking rather than temporary timing shifts.

Key Decisions for Investors

• No pre-emptive trade in ChemoMetec; wait for the release and only act if management changes the narrative on recurring revenue or margin durability.
• Use TMO and DHR as read-through longs only if the call confirms resilient consumables demand; otherwise keep them on the watchlist, not in the book.
• If the update is weak on order intake or FY guidance, pair long-quality tools vs short XBI for 1-3 months to express a funding-sensitive biotech vs resilient-tools divergence.
• Set an alert for any commentary on destocking or FX headwinds; those would be the cleanest signals to fade any post-earnings bounce in small-cap life-science tools.